PROVENT trial (PRJCA032503)
This cohort consists of raw 16s sequencing data from 89 post-rectal examination urine samples of male patients aged >16 years old with a histological diagnosis of prostate cancer with Gleason grade 6 or 7 and no previous treatment for prostate cancer. These patients were recruited to PROVENT (ClinicalTrials.gov ID: NCT03103152), a phase 2 placebo-controlled trial of two doses of aspirin (100 and 300mg) and one dose of Vitamin D (4,000 IU in nasal drops daily).